Sugi Predict

Sugi Predict / Compounds / SCHEMBL6168937

SCHEMBL6168937

SCHEMBL6168937

CC(C)(O)CC[C@H](C[C@H](O)[C@@H](N)Cc1cccc(F)c1)S(N)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 4/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CCR5 P51681 1/20 0.45
▸ SLC1A1 P43005 2/20 0.39
▸ REN P00797 2/20 0.38
▸ DPP4 P27487 4/20 0.34
▸ DPP7 Q9UHL4 2/20 0.34
▸ FAP Q12884 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ DPP9 Q86TI2 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CTSS P25774 1/20 0.32
▸ CTSK P43235 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ RIPK1 Q13546 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167191 0.87 CSNK1E (0.44) CCR1SLC1A1RENCSNK1E
SCHEMBL2676428 0.84 CCR1 (0.60) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL3825745 0.84 CCR1 (0.60) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL6169057 0.79 CSNK1E (0.43) CCR1SLC1A1RENCSNK1E
SCHEMBL6166479 0.76 CCR1 (0.49) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL4062779 0.75 CCR1 (0.51) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL6167922 0.75 CCR1 (0.42) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL6168085 0.75 CCR1 (0.42) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL6168256 0.74 CCR1 (0.41) CCR1CHRM2CCR5SLC1A1REN
SCHEMBL4070042 0.73 CCR1 (0.48) CCR1CHRM2CCR5SLC1A1REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1498417-A1 Heterocyclic amide derivatives Pfizer Products Inc. (US) 2005-01-19 — — EP claimed
US-6548671-B2 Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous PFIZER INC 2003-04-15 — — US claimed
US-20020132810-A1 Novel heterocyclic amide derivatives BROWN MATTHEW F (US) 2002-09-19 — — US claimed
EP-1498417-A1 Heterocyclic amide derivatives Pfizer Products Inc. (US) 2005-01-19 — — EP disclosed
US-6548671-B2 Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous PFIZER INC 2003-04-15 — — US disclosed
US-20020132810-A1 Novel heterocyclic amide derivatives BROWN MATTHEW F (US) 2002-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132810-A1 Novel heterocyclic amide derivatives ARG1, IL4, ARG2 CCR1 32/4885CHRM2 3307/4885CCR5 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.